Physician profile
Michael Waickman
NPI 1386644631
$9,836.10
in general payments reported to CMS, 2019-2025
36 companies · $1,798 in 2025
The $1,798 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,328 · 2020: $1,150 · 2021: $1,437 · 2022: $1,413 · 2023: $1,383 · 2024: $1,327 · 2025: $1,798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,418 · Education: $73.50 · Consulting Fee: $17.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,417.61 |
| Education | $73.50 |
| Consulting Fee | $17.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,527.10 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Abbvie INC. | $1,520.05 | 2019-2025 | Ubrelvy, Viberzi, Creon |
| Csl Behring | $941.55 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Glaxosmithkline, LLC. | $885.73 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $812.79 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $759.85 | 2019-2025 | Xolair |
| Genzyme Corporation | $566.73 | 2019-2024 | |
| Amgen INC. | $306.54 | 2021-2025 | Tezspire |
| Nestle Healthcare Nutrition INC. | $304.36 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $268.45 | 2019-2025 | |
| Optinose US, INC. | $208.28 | 2019-2025 | |
| Kaleo, INC. | $182.68 | 2019-2023 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $171.70 | 2020-2022 | |
| Vivus LLC | $155.52 | 2021-2025 | Qsymia |
| Grifols USA, LLC | $128.48 | 2020-2025 | Xembify, Prolastin-C Liquid |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Waickman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.